Literature DB >> 18826854

Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 - 5.

G Lehmann1, U Ott, D Kaemmerer, J Schuetze, G Wolf.   

Abstract

AIMS: Precise identification of renal osteodystrophy requires bone histomorphometry. Several markers of bone turnover may be useful to predict classification and severity of renal osteodystrophy, but there are only limited data whether these markers correlate with bone histomorphometry.
METHODS: In 36 patients with chronic kidney disease (CKD) Stage 3/4 and in 96 patients with CKD Stage 5 bone histomorphometry was performed and renal osteodystrophy was classified according to the standardized international nomenclature. Blood samples were taken at the time of bone biopsy, stored and analyzed at the end of the study.
RESULTS: Osteitis fibrosa (OF) was the most frequent histomorphometric form, occurred in 47.2% in CKD Stages 3 - 4 and in 61.4% in CKD Stage 5. There was no difference in the frequency of adynamic renal bone disease (ARBD). The correlation coefficients between bone turnover markers and histomorphometric parameters were higher in CKD 5 patients with high bone turnover lesions. The predictive value for high versus low/normal bone turnover status was comparable for alkaline phosphatase (APH), bone alkaline phosphatase (BAP), pyridinoline (Pyd), desoxypyridinoline (Dpyd), tartrat-resistent acid phosphatase (TRAP Vb) and parathyroid hormone (PTH) in CKD Stage 5 patients, but was insufficient for APH and TRAP Vb in CKD Stage 3 - 4 patients.
CONCLUSIONS: Besides parathyroid hormone, biochemical parameters of bone turnover provide a moderate discrimination and prediction of bone turnover status only in patients with CKD Stage 5. Due to a large variability, they are of limited use in predicting the histomorphometric type of renal osteodystrophy. Bone histology remains necessary for an exact classification of underlying pathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826854     DOI: 10.5414/cnp70296

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  27 in total

Review 1.  Biomarkers Predicting Bone Turnover in the Setting of CKD.

Authors:  Pieter Evenepoel; Etienne Cavalier; Patrick C D'Haese
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 2.  Bone Quality in Chronic Kidney Disease: Definitions and Diagnostics.

Authors:  Erin M B McNerny; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

3.  The utility of circulating markers to predict bone loss across the CKD spectrum.

Authors:  Thomas L Nickolas
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-19       Impact factor: 8.237

4.  Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.

Authors:  Hartmut H Malluche; Hanna W Mawad; Marie-Claude Monier-Faugere
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

Review 5.  Can one evaluate bone disease in chronic kidney disease without a biopsy?

Authors:  Revekka Babayev; Thomas L Nickolas
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

Review 6.  Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism.

Authors:  Armando L Negri; Vincent M Brandenburg; Vincent M Brandemburg
Journal:  Int Urol Nephrol       Date:  2014-01-03       Impact factor: 2.370

7.  Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.

Authors:  Syazrah Salam; Orla Gallagher; Fatma Gossiel; Margaret Paggiosi; Arif Khwaja; Richard Eastell
Journal:  J Am Soc Nephrol       Date:  2018-03-19       Impact factor: 10.121

Review 8.  Updates in CKD-Associated Osteoporosis.

Authors:  Pascale Khairallah; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 9.  Bone kidney interactions.

Authors:  Thomas L Nickolas; Sophie A Jamal
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 10.  Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.

Authors:  S N Salam; A Khwaja; M E Wilkie
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.